[go: up one dir, main page]

MA30393B1 - Procede de traitement, de diagnostic ou de detection du cancer - Google Patents

Procede de traitement, de diagnostic ou de detection du cancer

Info

Publication number
MA30393B1
MA30393B1 MA31346A MA31346A MA30393B1 MA 30393 B1 MA30393 B1 MA 30393B1 MA 31346 A MA31346 A MA 31346A MA 31346 A MA31346 A MA 31346A MA 30393 B1 MA30393 B1 MA 30393B1
Authority
MA
Morocco
Prior art keywords
diagnosing
treating
detecting cancer
methods
compositions
Prior art date
Application number
MA31346A
Other languages
English (en)
Inventor
Mary J Jantapour
Guoying Yu
Robert To
Vivien Chan
Deborah Zimmerman
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Publication of MA30393B1 publication Critical patent/MA30393B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne, entre autres choses, des procédés de traitement du cancer, des compositions de traitement du cancer et des procédés et compositions de diagnostic et/ou de dtection du cancer. En particulier, la présente invention concerne des compositions et des procédés de traitement, de diagnostic et de détection des cancers associés à une surexpression de LIV-1.
MA31346A 2006-04-13 2008-11-03 Procede de traitement, de diagnostic ou de detection du cancer MA30393B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79187106P 2006-04-13 2006-04-13

Publications (1)

Publication Number Publication Date
MA30393B1 true MA30393B1 (fr) 2009-05-04

Family

ID=38610188

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31346A MA30393B1 (fr) 2006-04-13 2008-11-03 Procede de traitement, de diagnostic ou de detection du cancer

Country Status (15)

Country Link
US (1) US20100196377A1 (fr)
EP (2) EP2407483A1 (fr)
JP (1) JP2009541208A (fr)
KR (1) KR20090010194A (fr)
CN (1) CN101622273A (fr)
AU (1) AU2007238636A1 (fr)
BR (1) BRPI0710616A2 (fr)
CA (1) CA2650126A1 (fr)
MA (1) MA30393B1 (fr)
MX (1) MX2008013121A (fr)
NO (1) NO20084795L (fr)
TN (1) TNSN08401A1 (fr)
TW (1) TW200813231A (fr)
WO (1) WO2007120787A2 (fr)
ZA (1) ZA200808669B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040141983A1 (en) 1999-03-15 2004-07-22 Protein Design Labs, Inc. Compositions against cancer antigen LIV-1 and uses thereof
WO2004067564A2 (fr) 2003-01-29 2004-08-12 Protein Design Labs, Inc. Compositions contre l'antgene cancereux liv-1 et leurs utilisations
US20120322075A1 (en) * 2009-10-26 2012-12-20 Externautics S.P.A. Lung Tumor Markers and Methods of Use Thereof
SG10201510041QA (en) * 2010-12-06 2016-01-28 Seattle Genetics Inc Humanized antibodies to liv-1 and use of same to treat cancer
EP3110391B1 (fr) * 2014-02-27 2018-01-31 The Procter and Gamble Company Méthode d'evaluation du zinc bio-disponible
KR20160045471A (ko) 2014-10-17 2016-04-27 대산안전산업 주식회사 방풍창이 구비된 방음패널
MA45324A (fr) 2016-03-15 2019-01-23 Seattle Genetics Inc Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique
SG11202004751TA (en) * 2017-12-01 2020-06-29 Seattle Genetics Inc Humanized anti-liv1 antibodies for the treatment of breast cancer
CN111289756A (zh) * 2018-12-10 2020-06-16 北京师范大学 卵巢癌肺转移成瘤相关的尿液标志物
GB201908208D0 (en) * 2019-06-10 2019-07-24 Univ College Cardiff Consultants Ltd An anti-mitotic agent
EP4029876A4 (fr) * 2019-09-09 2023-11-22 Zhejiang Baishoukangdi Co. Ltd. Procédé d'identification d'une substance capable d'affecter le vieillissement

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
WO1981001145A1 (fr) 1979-10-18 1981-04-30 Univ Illinois Medicaments "pro-drugs" pouvant etre actives par des enzymes hydrolytiques
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US5637677A (en) 1987-07-16 1997-06-10 The Trustees Of The University Of Pennsylvania Biologically active compounds and methods of constructing and using the same
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
AU631802B2 (en) 1988-06-14 1992-12-10 Cetus Oncology Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ZA902949B (en) 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
EP0521985B1 (fr) 1990-03-20 1997-09-24 The Trustees Of Columbia University In The City Of New York Anticorps chimeriques utilisant des ligands de liaison de recepteurs a la place de leur region constante
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
ES2178635T3 (es) 1990-11-09 2003-01-01 Stephen D Gillies Inmunoconjugados de citoquinas.
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
JP4157160B2 (ja) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
PL174721B1 (pl) 1992-11-13 1998-09-30 Idec Pharma Corp Przeciwciało monoklonalne anty-CD20
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
CA2132500A1 (fr) * 1994-09-20 1996-03-21 David Lockwood Manning Methodes pour predire l'evolution des tumeurs du sein
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
DK1500329T3 (da) 1996-12-03 2012-07-09 Amgen Fremont Inc Humane antistoffer, der specifikt binder TNF-alfa
US5830698A (en) 1997-03-14 1998-11-03 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US6475220B1 (en) 1999-10-15 2002-11-05 Whiteside Biomechanics, Inc. Spinal cable system
JP2003516124A (ja) 1999-10-15 2003-05-13 ユニバーシティー オブ マサチューセッツ 標的とした遺伝的干渉の手段としてのｒｎａ干渉経路遺伝子
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
CA2395832A1 (fr) * 2000-01-25 2001-08-02 Genentech, Inc. Compositions et methodes de traitement de cancer
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US7074175B2 (en) 2001-07-25 2006-07-11 Erik Schroeder Handy Thermotherapy via targeted delivery of nanoscale magnetic particles
US6997863B2 (en) 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
WO2003026577A2 (fr) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-aminobenzyl ether dans des agents d'administration de medicaments
BRPI0407031A (pt) * 2003-01-27 2006-01-17 Biogen Idec Inc Composições e métodos para tratamento de câncer empregando igsf9 e liv-1
WO2004067564A2 (fr) * 2003-01-29 2004-08-12 Protein Design Labs, Inc. Compositions contre l'antgene cancereux liv-1 et leurs utilisations
SI1651162T1 (sl) 2003-05-20 2016-02-29 Immunogen, Inc. Izboljšani citotoksični agenti, ki vsebujejo nove majtanzinoide
JP2007504842A (ja) * 2003-05-29 2007-03-08 ミレニアム ファーマシューティカルズ， インコーポレイテッド 乳癌の同定、評価、予防、および治療のための組成物、キットおよび方法
WO2005063301A1 (fr) * 2003-12-26 2005-07-14 Toshio Hirano Inducteur emt
US7504225B2 (en) * 2005-05-12 2009-03-17 Applied Genomics, Inc. Reagents and methods for use in cancer diagnosis, classification and therapy

Also Published As

Publication number Publication date
KR20090010194A (ko) 2009-01-29
WO2007120787A3 (fr) 2009-04-30
US20100196377A1 (en) 2010-08-05
CN101622273A (zh) 2010-01-06
CA2650126A1 (fr) 2007-10-25
TW200813231A (en) 2008-03-16
NO20084795L (no) 2009-01-13
JP2009541208A (ja) 2009-11-26
WO2007120787A2 (fr) 2007-10-25
BRPI0710616A2 (pt) 2011-08-16
AU2007238636A1 (en) 2007-10-25
EP2012827A2 (fr) 2009-01-14
MX2008013121A (es) 2009-03-25
ZA200808669B (en) 2009-10-28
EP2407483A1 (fr) 2012-01-18
TNSN08401A1 (en) 2010-04-14

Similar Documents

Publication Publication Date Title
MA30393B1 (fr) Procede de traitement, de diagnostic ou de detection du cancer
MX2009005058A (es) Metodos para tratar, diagnosticar o detectar cancer.
MA33747B1 (fr) Anticorps monoclonaux diriges contre la progastrine et leurs utilisations
TW200512298A (en) Method of diagnosing breast cancer
EA200901550A1 (ru) Способы лечения, диагностирования и выявления ассоциированных с fgf21 нарушений
EA200970891A1 (ru) Генетические варианты chr2 и chr16 в качестве маркеров для применения при оценке риска, диагностировании, прогнозировании и лечении рака молочной железы
EP1937845A4 (fr) Procédés et compositions à base de micro-arn pour le diagnostic, le pronostic et le traitement du cancer du sein
EP2179037A4 (fr) Procédés permettant un diagnostic, un pronostic et procédés de traitement
EA200702203A1 (ru) Способы и нуклеиновые кислоты для анализов клеточных пролиферативных нарушений
HK1199099A1 (en) Methods and compositions for the treatment and diagnosis of cancer
EP3070474A3 (fr) Procedes et compositions pour le diagnostic et le pronostic de lesion renale et d'insuffisance renale
ATE534752T1 (de) Tcl1-expression in durch mir-29 und mir-181 regulierter chronischer lymphozyten-leukämie (cll)
EP1978993A4 (fr) Compositions et procédés de diagnostic et de traitement du cancer
WO2009015050A3 (fr) Profil d'expression génique pour prédire la survie d'une patiente atteinte d'un cancer des ovaires
WO2010033773A3 (fr) Utilisations diagnostiques, pronostiques et thérapeutiques de mir dans des voies adaptatives et/ou des voies pathologiques
WO2007149948A3 (fr) Compositions et procédés de diagnostic et de traitement des tumeurs
MX336280B (es) Metodos y composiciones para diagnosticos y pronosticos de lesion renal y falla renal.
WO2009019370A3 (fr) Procede de dosage de l'apolipoproteine aii pour le diagnostic in vitro du cancer colorectal
WO2010033597A3 (fr) Procédés pour détecter une surexpression de sparc et procédés thérapeutiques et diagnostiques associés à ceux-ci
MA33091B1 (fr) Combinaisons pharmaceutiques comprenant rdea119/bay 869766 pour le traitement de cancers specifiques
EP2073843A4 (fr) Procédés de diagnostic, de traitement, ou de prévention de troubles liés aux cellules plasmatiques
WO2022043930A3 (fr) Biomarqueurs pour la thérapie anticancéreuse utilisant des antagonistes de mdm2
WO2009139853A3 (fr) Anticorps monoclonaux humains dirigés contre le récepteur de chimiokines humaines ccr7
BR112015021507A8 (pt) métodos e composições para o diagnóstico de pré-eclampsia em uma mulher grávida e kit de ensaio de diagnóstico
WO2008092002A3 (fr) Compositions et procédés pour le traitement et le diagnostic du cancer du pancréas